Global Thrombopoietin Receptor Agonist Market Size, Share and Trends Analysis Report, By Type (Peptide Agent, Small Molecule Agent), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Forecast (2022-2028)

The global thrombopoietin receptor agonist market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The market is driven by growing awareness of infectious diseases and the need for robust infection control procedures in all health care settings, the growing number of new medical equipment being brought to hospitals, and the growing demand for international autopsy services from different countries. Thrombopoietin receptor agonist market size is expected to record significant growth due to the wide range of use of the small molecule performed in pathology laboratories and other healthcare facilities. In addition, according to the WHO, the incidence of thrombopoietin receptor agonistsin adults is estimated at 32 million per year. The increase in the disease is expected to create market demand during the forecast period. Regular awareness campaigns by thrombopoietin receptor agonist support organizations in developed countries have been instrumental in informing more people about this disease which could further increase the thrombopoietin receptor agonist market growth.
The increase in the prevalence of peptide agents has created a demand for the development of new metal cleaning products for its foam manufacturing which in turn drives the global thrombopoietin receptor agonist market growth. In addition, leading pharmaceutical companies are focusing on the development of manufacturing the foam substance, and the market growth is driven by the strong focus of the pharmaceutical companies and research organizations on the R&D of the prevalence of peptide agents has increased the production of methylene dichloride market.
In April 30, 2020, Dova Pharmaceuticals, a Swedish company, announced the launch of DOPTELET, a thrombopoietin receptor agonist used to treat immune thrombocytopenia. The product has been approved by the China National Medical Products Administration (NMPA) for elderly patients with chronic liver disease. The drug was approved based on a double-blind, placebo-controlled study performed on patients with severe thrombocytopenia and chronic liver disease when patients receiving DOPTELET were found to be significantly better than the results of a placebo study. Launch of such products is further expected to drive the market growth.

 

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Type
By Distribution Channel

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape-
Amgen Inc., Novartis International AG, Rigel Pharmaceuticals Global Scientific Inc., and Merck & Co., Inc., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Thrombopoietin Receptor Agonist Market Report by Segment
By Type
Peptide Agent
Small Molecule Agent
By Distribution Channel
HospitalsPharmacy
Retail Pharmacy
Online Pharmacy
Others